Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study

Swedish registry review (25,466 people post MI event) found that although most were receiving high intensity statins (86.6%), 50.7% were eligible for PCSK9i’s according to ESC/EAS guidelines. Tthe financial implications of these new guidelines are therefore substantial.

Source:

European Heart Journal